Healthcare
PhaseRx, Inc.(PZRXQ)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- โ
- Revenue Growth
- -100.0%
- EPS Growth
- -185.1%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PhaseRx, Inc. (PZRXQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -185.1%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -185.1%, free cash flow -63.8% with operating margin 0.0% and ROIC -122.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PZRXQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2018 was reported on Mar 29, 2018, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -185.1%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2018 Mar 29, 2018 | โ | +0.0% | +0.0% | +0.0% |
2017 Nov 9, 2017 | +28.1% | +0.0% | +0.0% | +0.0% |
2017 Aug 10, 2017 | +14.3% | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PZRXQ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PZRXQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PZRXQ and SPY.
Company Overview
PhaseRx, Inc.
Other OTC
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.
- Leadership
- Robert W. Overell
- IPO Date
- May 18, 2016
- Employees
- 10
- Street Address
- 410 West Harrison Street
- Mailing
- Seattle, WA, 98119
- Region
- Seattle, WA, US
- Reporting Currency
- USD
- Investor Line
- 206 805 6300
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.2
- Price/Sales
- โ
- Price/Book
- 0.0
Growth
- Revenue
- -100.0%
- EPS
- -185.1%
- Free Cash Flow
- -63.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 101.7%
- ROIC
- -122.2%
Balance Sheet
- Debt/Equity
- 0.61
- Current Ratio
- 7.99
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.